Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Werewolf Therapeutics Inc HOWL

Healthcare Biotechnology
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies... see more

Current News (NDAQ:HOWL)

Werewolf Therapeutics Announces Pipeline and Business Updates

GlobeNewswire December 18, 2025

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

GlobeNewswire November 7, 2025

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 4, 2025

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

GlobeNewswire October 8, 2025

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

GlobeNewswire October 3, 2025

Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 2, 2025

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 14, 2025

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

GlobeNewswire July 9, 2025

Werewolf Therapeutics to Participate in the BIO International Convention

GlobeNewswire June 12, 2025
View More News ››

Opinion & Analysis (NDAQ:HOWL)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:HOWL)

Be the first to post on this bullboard.

Algernon Health Inc.

Algernon Health Inc.

Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company ...
View More »

Podcasts